2023 News Archive - UCLA Institute of Urologic Oncology

December 8, 2023 -  Decoding the Metabolic Shift Behind Prostate Cancer Drug Resistance – Andrew Goldstein – Continued coverage of an interview with Dr. Andrew Goldstein, associate professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine, member of the UCLA Health Jonsson Comprehensive Cancer Center, and member of the Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research at UCLA.

December 5, 2023 - Technology Networks Why Do Some Prostate Cancers Become Resistant to Hormone Therapy? – Coverage of a UCLA study led by Dr. Andrew Goldstein, associate professor of molecular, cell, and developmental biology and urology at the David Geffen School of Medicine. 

Additional Coverage: News-Medical, ScienceDaily, eCancer, UCLA Health Newsroom. 

September 6, 2023 - PSA Levels After Prostate Cancer Treatment May Not Predict Survival Rate. 
Healthline provides coverage of study led by Dr. Amar Kishan, a member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA. Additional coverage: eCancer, Medscape and Urology Times. 

August 28, 2023 - Study challenges the use of biochemical recurrence as a prostate cancer predictor. Dr. Amar Kishan, a member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, provided expert commentary to News-Medical.

August 25, 2023 - Tool helps improve the accuracy of focal therapy for prostate cancer. Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA provided expert commentary to the Urology Times. 

August 9, 2023 - Urology Times PSMA-PET shows value as a prognostic biomarker for recurrence in prostate cancer. Continued coverage of new UCLA and UCSF study. Dr. Loïc Djaïleb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author. Additional coverage: CancerNetwork, Physician's Weekly Online Urology Times PSMA-PET shows value as a prognostic biomarker for recurrence in prostate cancer –Continued coverage of new UCLA and UCSF study. Dr. Loïc Djaïleb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author. Additional coverage: CancerNetwork, Physician's Weekly Online 

July 25, 2023 - PSMA PET imaging improves accuracy of predicting prostate cancer recurrence. A molecular imaging tool developed by researchers at the University of California's two nationally ranked medical centers, UCLA and UCSF, helps improve the accuracy of predicting the risk of cancer recurrence in patients with intermediate to high-risk prostate cancer who undergo surgery. Dr. Jeremie Calais and Dr. Robert Reiter are study authors.  

July 25, 2023 - PSMA PET imaging improves accuracy of predicting prostate cancer recurrence. Medical Express and eCancer covered the new UCLA and UCSF study. Dr. Loic Djaileb, a visiting associate professor at the David Geffen School of Medicine at UCLA is the study's first author, with Dr. Jeremie Calais, an associate professor and director of the Clinical Research Program of the Ahmanson Translational Theranostics Division in the Department of Molecular and Medical Pharmacology at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center as co-senior author.

July 12, 2023 - Researchers awarded $2 million grant from National Cancer Institute. Researchers from the UCLA Health Jonsson Comprehensive Cancer Center, including Dr. Christine Mona, Dr. Caius Radu, Dr. Johannes Czernin, have been awarded a $2 million grant from the National Cancer Institute to design better combination therapies that target the immune system to treat metastatic castration-resistant prostate cancer, which continues to spread even when testosterone levels are significantly reduced.

June 29, 2023 - Dr. Jeremie Calais, associate professor at the David Geffen School of Medicine at UCLA, director of the Ahmanson Translational Theranostics Division's clinical research program and member of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, provided expert commentary to Diagnostic Imaging about how new research shows viability of PET imaging agent for clear cell renal carcinoma. 

June 27, 2023 - Scienmag and News-Medical provided coverage of a new study led by Dr. Leonard Marks, professor and deKernion Endowed Chair in Urology at the David Geffen School of Medicine at UCLA and member of UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, about how an AI model could help improve outcomes of prostate cancer focal therapy.

June 23, 2023 - Dr. Andrew Goldstein, associate professor of molecular, cell and developmental biology and urology at the David Geffen School of Medicine at UCLA, received an Idea Development Award from the Department of Defense to study how metabolism changes in prostate cancer as a result of hormone therapy, the most commonly used treatment for men with advanced disease.

June 21, 2023 - Uro Today interviewed Dr. Jeremie Calais, associate professor at the David Geffen School of Medicine at UCLA, director of the Ahmanson Translational Theranostics Division's clinical research program and member of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Molecular Imaging, Nanotechnology and Theranostics Program, about PSMA PET's influence on Prostate Cancer Studies. Dr. Calais was also interviewed for another story on Navigating Salvage Radiotherapy with Insights from PSMA PET. 

June 6, 2023 - Dr. Paul Boutros, vice dean of research, professor in human genetics and urology at the David Geffen School of Medicine at UCLA. Provided expert commentary to USA Today regarding DNA sequencing for cancer patients.

June 2, 2023 - Dr. Isla P. Garraway, associate professor of urology at the David Geffen School of Medicine at UCLA, member of the UCLA Health Jonsson Comprehensive Cancer Center, and member of the Broad Center for Regenerative Medicine and Stem Cell Research at UCLA, discusses the unique aspects of prostate cancer research within the VA healthcare system on UroToday.

May 23, 2023
Reprint of press release highlighting UCLA physicians and scientists presenting at the American Society of Clinical Oncology's annual meeting, including a presentation by Dr. Brian Shuch, Associate Professor of Urology, Director of the Kidney Cancer Program, and Meinhardt Chair for Kidney Cancer Research, regarding the results from the phase 3 ZIRCON study. 

May 8, 2023 - Dr. Brian Shuch, Director of the Kidney Cancer Program and the Alvin & Carrie Meinhardt Endowed Chair in Kidney Cancer Research at UCLA, provided expert commentary to Cancer Network about how imaging with 89Zr-DFO-Girentuximab may better identify kidney tumors.

April 25, 2023 - Dr. Wayne Brisbane, assistant professor of urology at the David Geffen School of Medicine at UCLA, provided expert commentary to Urology Times about Unfold AI, an artificial intelligence (AI)–powered software application program, being used for the management of patients with prostate cancer. 

April 23, 2023 - UCLA Health reports about how researchers create a framework for evaluating how fast a cancer will grow. An international team of researchers led by UCLA's Dr. Paul Boutros, professor in the departments of human genetics and urology and interim vice dean for research at the David Geffen School of Medicine at UCLA and director of the UCLA Health Jonsson Comprehensive Cancer Center's Cancer Data Science program, have created a new way to accurately estimate how fast an individual cancer is evolving using open-source software, which makes big data sets easily accessible to the public. The findings can be used to develop more highly targeted cancer treatments. A paper detailing their method is published online in the journal of Nature Biotechnology.

April 3, 2023 - Nazy Zomorodian, NP, Director of the Genitourinary Clinical Trials Unit and Assistant Professor and Nurse Practitioner for the UCLA Urology, provided commentary to cancernetwork regarding the FDA's approval  of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) as a combination therapy for patients with urothelial cancer. 

April 3, 2023 - Dr. Amar Kishan, member of the IUO, UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, discusses GI toxicity reduction with MRI-Guided SBRT in prostate cancer with OncLive.

March 10, 2023 - Dr. Matthew B. Rettig, medical director of the Prostate Cancer Program at the Institute of Urologic Oncology at UCLA, appeared on OncLive to discuss the evolution of triplet therapy within the landscape of metastatic hormone-sensitive prostate cancer.

March 10, 2023 - Expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the UCLA Health Jonsson Comprehensive Cancer Center and the Institute of Urologic Oncology at UCLA, was provided to OncLive about the role of PSMA-PET imaging in metastatic-castrate resistant prostate cancer.

February 23, 2023 - MedPageToday interviewed Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, about the optimal sequencing of ADT in nonmetastatic prostate cancer.

February 21, 2023 - Dr. Matthew Rettig, medical director of the Prostate Cancer Program at the Institute of Urologic Oncology at UCLA, provided expert commentary to OncLive about new options for metastatic prostate cancer.

February 3, 2023 - Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, provided expert commentary to Healio News regarding World Cancer Day and practical advice for care.

February 2, 2023 - Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, met with OncLive to discuss how MRI-guided SBRT could represent a safer, more precise radiotherapy option for prostate cancer.

January 30, 2023 - OncLive interviewed Dr. Amar Kishan, member of the UCLA IUO and UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, about the MIRAGE trial for prostate cancer.

January 18, 2023 - Continued coverage in The ASCO POST of UCLA research led by Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA. Additional coverage: MedPage Today, eCancer, MIMS Urology

January 13, 2023 - UroToday/GU Onc Today reports that Dr. Isla P. Garraway, associate professor of urology at the David Geffen School of Medicine at UCLA, member of the UCLA Health Jonsson Comprehensive Cancer Center and member of the Broad Center for Regenerative Medicine and Stem Cell Research at UCLA, is a featured panelist on the Prostate Cancer Foundations's newly established health equities panel creating prostate cancer screening guidelines for Black men in the United States.

January 12, 2023 - Technology Networks reports on new UCLA research led by Dr. Amar Kishan, member of the UCLA Health Jonsson Comprehensive Cancer Center and assistant professor and chief of genitourinary oncology service at UCLA, that shows that MRI-guided radiotherapy improves treatment for localized prostate cancer.

January 10, 2023 - MRI-guided radiotherapy produces fewer side effects and better quality of life for patients with localized prostate cancer according to new research, led by Dr. Amar Kishan, from the first randomized phase III clinical trial to directly compare MRI-guided stereotactic body radiotherapy (SBRT) with the same therapy guided by CT are published in JAMA Oncology and highlighted by the UCLAHealth Newsroom.

January 10, 2023 - UroToday/GU Onc Today provides expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the IUO, about PSMA PET imaging in clinical practice.

January 3, 2023 - UroToday/GU Onc Today provides expert commentary from Dr. Jeremie Calais, assistant professor of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA and member of the IUO, about PSMA PET imaging in clinical practice.

January 2, 2023 - Urology Times provides expert commentary from Dr. Karim Chamie, associate professor of urology at the David Geffen School of Medicine at UCLA, about the interim findings from an ongoing study (NCT03022825) looking at the safety and efficacy of combining Nogapendekin alfa inbakicept (NAI) with BCG intravesical instillation for the treatment of BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC).1